Endocrine

DRUG2 trials

Sponsors

Baylor Breast Care Center, Universidade Federal do Ceará

Conditions

Breast CancerClimacteric

Phase 2

Lapatinib and Trastuzumab With or Without Endocrine Therapy

CompletedNCT00548184

Baylor Breast Care CenterBreast Cancer

Start: 2008-05-31End: 2014-01-31Updated: 2019-11-07

Unknown Phase

Auriculotherapy for Sexual Function in Menopausal women

Active, not recruitingRBR-5t96cx6

Universidade Federal do CearáClimacteric

Start: 2024-09-20Updated: 2025-10-27

Related Papers

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

2019-06-0135 citations

Abstract P6-17-12: Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive <i>in vivo</i> breast cancer models

Cancer Research2019-02-15

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

Journal of Clinical Oncology2018-05-2015 citations

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

2017-11-0773 citations